New Late-breaking Data from Medtronic Evolut Low Risk Trial Demonstrate Strong Clinical and Cost-effectiveness Benefits of TAVR Platform

CRT 2024: Evolut TAVR is a safe, effective, and economically cost-effective treatment option for low-risk severe aortic stenosis patients compared to surgery up to four years

Related Keywords

Basel Ramlawi ,Corevalve Evolut ,Nina Goodheart ,Medtronic Evolut ,Davidj Cohen ,Outcomes Research ,Academic Affairs At St ,Cardiovascular Research Foundation ,Medtronic ,Columbia University ,Cardiovascular Research Technologies ,Lankenau Heart Institute ,Cardiothoracic Surgery At Main Line Health System ,Evolut Low Risk ,Evolut Low Risk Trial ,Senior Vice President ,Structural Heart ,Cardiovascular Portfolio ,Low Risk Trial ,Academic Affairs ,Francis Hospital ,Year Outcomes ,Contemporary Valves Versus Self Expanding ,System Chief ,Cardiothoracic Surgery ,Main Line Health System ,Lankenau Heart ,